<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03213977</url>
  </required_header>
  <id_info>
    <org_study_id>DLBCL-005</org_study_id>
    <nct_id>NCT03213977</nct_id>
  </id_info>
  <brief_title>R-DA-EDOCH Versus R-CEOP90, w/o Upfront Auto-HSCT in Young Patients With Intermediate/High-risk DLBCL</brief_title>
  <official_title>A Multicenter,Randomized, Controlled (Comparative), Open, Prospective Study Evaluating an Efficacy of R-DA-EPOCH and R-CEOP90, With or Without Upfront Auto-HSCT，in Newly Diagnosed Young Patients With Intermediate/High-risk DLBCL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients initially are randomized into 4 arms:&#xD;
&#xD;
      Arm I: R-DA-EPOCH; Arm II: R-DA-EPOCH + auto-SCT; Arm III: R-CEOP90; Arm IV: R-CEOP90 +&#xD;
      auto-SCT.&#xD;
&#xD;
      Patients who achieved complete remission (CR) or partial remission (PR) after 6 cycles of&#xD;
      R-DA-EPOCH or R-CEOP 90, continue to have 2 more cycles for consolidation in each arm (Arm I&#xD;
      and Arm III), or undergo stem cell harvest and auto-HSCT following standard institutional&#xD;
      protocols. (Arm II and Arm IV).&#xD;
&#xD;
      The overall purpose of the study is to determine if R-CEOP90 followed by auto-HSCT has&#xD;
      similar efficacy compared to that with R-DA-EPOCH.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>Two-year survival</time_frame>
    <description>Time to disease progression is calculated in months from day of enrollment in the study until disease progression, as appropriate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete response</measure>
    <time_frame>168 day</time_frame>
    <description>(physical examination, standard blood tests, including assessment of LDH level, thoracic and abdominal computerized tomography (together with any other anatomic site, as clinically indicated), bone marrow biopsy in case of bone marrow involvement and 18F-fludeoxyglucose positron emission tomography (18FDG-PET) (not mandatory) in case of residual measurable disease at the end of the chemoimmunotherapy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>Two-year survival</time_frame>
    <description>Survival time is calculated in months from day of enrollment in the study until death, as appropriate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Up tp study day 240</time_frame>
    <description>Adverse Events (AEs) occurring during the protocol-specified reporting period are documented.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">475</enrollment>
  <condition>Diffuse Large B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I:R-DA-EPOCH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protocol involves 8 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II:R-DA-EPOCH + auto-HSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III:R-CEOP90</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Protocol involves 8 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV:R-CEOP90 + auto-HSCT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Protocol involves 6 cycles. Patients with complete remission or partial remission undergo auto-HSCT after 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-DA-EPOCH</intervention_name>
    <description>R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.</description>
    <arm_group_label>Arm I:R-DA-EPOCH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-DA-EPOCH + auto-HSCT</intervention_name>
    <description>R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.</description>
    <arm_group_label>Arm II:R-DA-EPOCH + auto-HSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CEOP90</intervention_name>
    <description>R-CEOP90 treatment without auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.</description>
    <arm_group_label>Arm III:R-CEOP90</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CEOP90 + auto-HSCT</intervention_name>
    <description>R-CEOP90 treatment with auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.</description>
    <arm_group_label>Arm IV:R-CEOP90 + auto-HSCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 16-60 years&#xD;
&#xD;
          -  Newly diagnosed DLBCL&#xD;
&#xD;
          -  No previous treatment with chemotherapy and/or radiation therapy of DLBCL&#xD;
&#xD;
          -  Presence of 2 or more signs of unfavorable prognosis (IPI 2-4)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2&#xD;
&#xD;
          -  Life expectancy of ≥ 6 months&#xD;
&#xD;
          -  Adequate hematological function&#xD;
&#xD;
          -  Offer informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Transformation of mature cell lymphomas in DLBCL&#xD;
&#xD;
          -  Pretreated DLBCL&#xD;
&#xD;
          -  HIV-associated DLBCL&#xD;
&#xD;
          -  Concomitant other cancer&#xD;
&#xD;
          -  Congestive heart failure, unstable angina, severe cardiac arrhythmias and conduction&#xD;
             disturbances, myocardial infarction&#xD;
&#xD;
          -  Renal insufficiency (serum creatinine greater than 0.2 mmol/L) (except cases with&#xD;
             specific kidney infiltration, urinary tract compression by tumor conglomerate or&#xD;
             presence of uric acid nephropathy due to massive cytolysis syndrome)&#xD;
&#xD;
          -  Liver failure (except cases with liver tumor infiltration), acute hepatitis or active&#xD;
             phase of chronic hepatitis B or C with serum bilirubin greater than 1.5 standards,&#xD;
             alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 3&#xD;
             standards, prothrombin index less than 70%&#xD;
&#xD;
          -  Severe pneumonia (except cases with specific lungs infiltration), accompanied by&#xD;
             respiratory failure (dyspnea &gt; 30 in min., hypoxemia less than 70 mm Hg, when it is&#xD;
             impossible to compensate situation in 2-3 days)&#xD;
&#xD;
          -  Life-threatening bleeding (gastrointestinal, intracranial), with exception of bleeding&#xD;
             due to tumor infiltration of organs (stomach, intestines, uterus, etc.) and&#xD;
             disseminated intravascular coagulation due to underlying disease complications after&#xD;
             their successful conservative treatment&#xD;
&#xD;
          -  Severe mental disorders (delusions, severe depressive syndrome and other&#xD;
             manifestations of productive symptoms) not related with specific infiltration of&#xD;
             central nervous system&#xD;
&#xD;
          -  Decompensated diabetes&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianda Hu, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fujian Medical University Union Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jianda Hu, Prof.</last_name>
    <phone>86-13959169016</phone>
    <email>drjiandahu@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ting Yang, Prof.</last_name>
    <phone>86-13950210357</phone>
    <email>yang.hopeting@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianda Hu, Prof.</last_name>
      <phone>86-13959169016</phone>
      <email>drjiandahu@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Ting Yang, Prof.</last_name>
      <phone>86-13950210357</phone>
      <email>yang.hopeting@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jianda Hu, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2017</study_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Jianda Hu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>DLBCL, R-DA-EPOCH, R-CEOP90, auto-HSCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

